Purpose
To present pilot toxicity and survival outcomes for a prospective trial investigating adaptive radiotherapy (ART) for oropharyngeal squamous cell carcinoma.
Methods
Twenty-four patients enrolled onto an IRB-approved clinical trial. Twenty-two patients were analyzed. Daily CT-guided setup and deformable image registration permitted serial mapping of CTVs and avoidance structures for ART planning. Primary site was base of tongue in 15 patients, tonsil in 6, and glossopharyngeal sulcus in 1. Twenty (91%) patients had AJCC stage IV disease. T stage distribution was 2 T1, 12 T2, 3 T3, 5 T4 and N stage distribution was 1 N0, 2 N1, 5 N2a, 12 N2b, and 2 N2c. Twenty-one (95%) patients received systemic therapy.
Results
With 31 month median follow up (range: 13-45), there has been no primary site failure and 1 nodal relapse, yielding 100% local and 95% regional disease control at 2 years. Baseline tumor size correlated with absolute volumetric treatment response (p = 0.018). Parotid volumetric change correlated with duration of feeding tube placement (p = 0.025). Acute toxicity was comparable to conventional IMRT results. Chronic toxicity and functional outcomes beyond 1 year were tabulated.
Discussion
This is the first prospective evaluation of morbidity and survival outcomes in patients with locally advanced head and neck cancer treated with automated adaptive replanning. ART can provide dosimetric benefit with only 1 or 2 mid-treatment replanning events. Our preliminary clinical outcomes document functional recovery and preservation of disease control at one-year follow-up and beyond.
Diabetes, a global epidemic, has become a serious threat to public health. The present study is aimed at constructing an injectable thermosensitive PEG-polyester hydrogel formulation of liraglutide (Lira), a "smart" antidiabetic polypeptide, in the long-acting treatment of type 2 diabetes mellitus. A total of three thermosensitive poly(ε-caprolactone-co-glycolic acid)-poly(ethylene glycol)-poly(ε-caprolactone-co-glycolic acid) (PCGA-PEG-PCGA) triblock copolymers with similar molecular weights but different ε-caprolactone-to-glycolide (CL-to-GA) ratios were synthesized. The polymer aqueous solutions exhibited free-flowing sols at room temperature and formed in situ hydrogels at body temperature. While the different bulk morphologies, stabilities of aqueous solutions, and the varying in vivo persistence time of hydrogels in ICR mice were found among the three copolymers, all of the Lira-loaded gel formulations exhibited a sustained drug release manner in vitro regardless of CL-to-GA ratios. The specimen with a powder form in the bulk state, a stable aqueous solution before heating, and an appropriate degradation rate in vivo was selected as the optimal carrier to evaluate the in vivo efficacy. A single injection of the optimal gel formulation showed a remarkable hypoglycemic efficacy up to 1 week in diabetic db/db mice. Furthermore, three successive administrations of this gel formulation within one month significantly lowered glycosylated hemoglobin and protected islets of db/db mice. As a result, a promising once-weekly delivery system of Lira was developed, which not only afforded long-term glycemic control but also significantly improved patient compliance.
In treatment of diabetes, it is much desired in clinics and challenging in pharmaceutics and material science to set up a long-acting drug delivery system. This study was aimed at constructing a new delivery system using thermogelling PEG/polyester copolymers. Liraglutide, a fatty acid-modified antidiabetic polypeptide, was selected as the model drug. The thermogelling polymers were presented by poly(ε-caprolactone-co-glycolic acid)-poly(ethylene glycol)-poly(ε-caprolactone-co-glycolic acid) (PCGA-PEG-PCGA) and poly(lactic acid-co-glycolic acid)-poly(ethylene glycol)-poly(lactic acid-co-glycolic acid) (PLGA-PEG-PLGA). Both the copolymers were soluble in water, and their concentrated solutions underwent temperature-induced sol-gel transitions. The drug-loaded polymer solutions were injectable at room temperature and gelled in situ at body temperature. Particularly, the liraglutide-loaded PCGA-PEG-PCGA thermogel formulation exhibited a sustained drug release manner over one week in both in vitro and in vivo tests. This feature was attributed to the combined effects of an appropriate drug/polymer interaction and a high chain mobility of the carrier polymer, which facilitated the sustained diffusion of drug out of the thermogel. Finally, a single subcutaneous injection of this formulation showed a remarkably improved glucose tolerance of mice for one week. Hence, the present study not only developed a promising long-acting antidiabetic formulation, but also put forward a combined strategy for controlled delivery of polypeptide.
Highlights A fast and efficient method was developed for the synthesis of HKUST-1 Synthesis was conducted under low temperature and atmospheric pressure The MOFs was synthesized in nano-scale with high BET surface area and high yield Activation agent has shown significant influence on BET surface area of the MOFs The HKUST-1 prepared shows excellent CO2 uptake capacity 2
Diabetes and its
complications have become a global challenge of
public health. Herein, we aimed to develop a long-acting delivery
system of lixisenatide (Lixi), a glucose-dependent antidiabetic peptide,
based on an injectable hydrogel for the synchronous treatment of type
2 diabetes mellitus (T2DM) and associated complications. Two triblock
copolymers, poly(ε-caprolactone-co-glycolic
acid)–poly(ethylene glycol)–poly(ε-caprolactone-co-glycolic acid) and poly(d,l-lactic
acid-co-glycolic acid)–poly(ethylene glycol)–poly(d,l-lactic acid-co-glycolic acid)
possessing temperature-induced sol–gel transitions, were synthesized
by us. Compared to the two single-component hydrogels, their 1/1 mixture
hydrogel not only maintained the temperature-induced gelation but
also exhibited a steadier degradation profile in vivo. Both in vitro
and in vivo release studies demonstrated that the mixture hydrogel
provided the sustained release of Lixi for up to 9 days, which was
attributed to balanced electrostatic interactions between the positive
charges in the peptide and the negative charges in the polymer carrier.
The hypoglycemic efficacy of Lixi delivered from the mixture hydrogel
after a single subcutaneous injection into diabetic db/db mice was
comparable to that of twice-daily administrations of Lixi solution
for up to 9 days. Furthermore, three successive administrations of
the abovementioned gel system within a month significantly increased
the plasma insulin level, lowered glycosylated hemoglobin, and improved
the pancreatic function of the animals. These results were superior
or equivalent to those of twice-daily injections of Lixi solution
for 30 days, but the number of injections was markedly reduced from
60 to 3. Finally, an improvement in hyperlipidemia, augmentation of
nerve fiber density, and enhancement of motor nerve conduction velocity
in the gel formulation-treated db/db mice indicated that the sustained
delivery of Lixi arrested and even ameliorated diabetic complications.
These findings suggested that the Lixi-loaded mixture hydrogel has
great potential for the treatment of T2DM with significant improvements
in the health and quality of life of patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.